Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 35: 146-151, 1989;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hansen, H. J.
Right arrow Articles by Goldenberg, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hansen, H. J.
Right arrow Articles by Goldenberg, D. M.

Clinical Chemistry, Vol 35, 146-151, Copyright © 1989 by American Association for Clinical Chemistry

Solving the problem of antibody interference in commercial "sandwich"- type immunoassays of carcinoembryonic antigen

HJ Hansen, G LaFontaine, ES Newman, MK Schwartz, A Malkin, K Mojzisik, EW Martin and DM Goldenberg
Immunomedics, Inc., Newark, NJ 07103.

We evaluated the effect of human anti-murine antibodies (HAMA) on apparent concentrations of carcinoembryonic antigen (CEA) as measured in serum with commercial enzyme immunoassay (EIA) kits manufactured by Abbot ("two-step" double monoclonal antibody assay), Roche, and Hybritech (room-temperature protocol). In sera from patients given parenteral murine monoclonal antibody for experimental diagnostic and immunotherapy studies, HAMA titers were determined with Immunomedics' "ImmuSTRIP HAMA-EIA" kit reagents. "True" CEA titers were established by using the ImmuCEA/MA-EIA and heat-extraction to destroy HAMA before assay for CEA. The concordance of the ImmuCEA/MA assay with the Abbott and Roche CEA EIAs was established with sera from normal individuals and from patients who had not received parenteral injections of murine monoclonal antibody. At high (100 mg/L) concentrations of HAMA, false- positive results were observed with all three kits. The Hybritech and Roche assays were more sensitive to interference by HAMA than was the Abbott CEA-EIA, false-positive results being observed at HAMA concentrations between 1 and 10 mg/L. Similar sensitivity of the three kits to interference by primate anti-MAb sera was demonstrated. Use of primate anti-MAb sera to create controls with HAMA activity and of analyte is recommended to evaluate MAb assays for potential HAMA interference and for use to devise methods to eliminate HAMA interference.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
J. Bjerner, O. P. Bormer, and K. Nustad
The War on Heterophilic Antibody Interference
Clin. Chem., January 1, 2005; 51(1): 9 - 11.
[Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
R. L. Bertholf, L. Johannsen, and G. Benrubi
False Elevation of Serum CA-125 Level Caused by Human Anti-Mouse Antibodies
Ann. Clin. Lab. Sci., October 1, 2002; 32(4): 414 - 418.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
R. J. Doerr, H. Abdel-Nabi, and B. Merchant
Indium 111 ZCE-025 Immunoscintigraphy in Occult Recurrent Colorectal Cancer With Elevated Carcinoembryonic Antigen Level
Arch Surg, February 1, 1990; 125(2): 226 - 229.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American Association for Clinical Chemistry.